Angelo Labate1,2, Francesco Fortunato3, Alessia Giugno3, Iolanda Martino3, Maria Eugenia Caligiuri4, Antonio Gambardella3,4. 1. Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. labate@unicz.it. 2. Neuroscience Research Center, Magna Graecia University, Viale Europa, 88100, Catanzaro, Italy. labate@unicz.it. 3. Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. 4. Neuroscience Research Center, Magna Graecia University, Viale Europa, 88100, Catanzaro, Italy.
Abstract
PURPOSE: To evaluate the efficacy of perampanel (PER) in patients with a diagnosis of mesial temporal lobe epilepsy (MTLE) taking PER as first add-on option due to inefficacy of first antiepileptic drug (AED), rather than late add-on choice. METHODS: Thirty-seven MTLE patients aged ≥ 12 years were recruited consecutively with a minimum duration of follow-up of 1 year and intermediate follow-up of 3 months. Patients were divided into two groups: 20/37 taking PER as first add-on due to inefficacy of first AED (first group) and 17/37 taking PER as late add-on due to inefficacy of ≥ 2 AEDs (second group). Efficacy, retention rate, and safety were evaluated. RESULTS: At 3 months, the 70% of the first group had a reduction > 50% of seizure frequency, with six patients becoming also seizure free, while in the second group, only the 23.5% had a reduction > 50% of seizure frequency and none became seizure free (p = 0.005). Six patients of first group were also switched to a monotherapy of PER and five out of six remained seizure free at 12 months. At 1 year of follow-up, efficacy of PER was 70% for the first group, while only of 29.4% for the second group (p = 0.014). Retention rate of the first group at 3 months and 1 year was 85%, while for the second group was, respectively, 82.3% and 64.7%. CONCLUSION: PER was significantly successful and tolerated in MTLE patients when used as first add-on option rather than as late add-on.
PURPOSE: To evaluate the efficacy of perampanel (PER) in patients with a diagnosis of mesial temporal lobe epilepsy (MTLE) taking PER as first add-on option due to inefficacy of first antiepileptic drug (AED), rather than late add-on choice. METHODS: Thirty-seven MTLE patients aged ≥ 12 years were recruited consecutively with a minimum duration of follow-up of 1 year and intermediate follow-up of 3 months. Patients were divided into two groups: 20/37 taking PER as first add-on due to inefficacy of first AED (first group) and 17/37 taking PER as late add-on due to inefficacy of ≥ 2 AEDs (second group). Efficacy, retention rate, and safety were evaluated. RESULTS: At 3 months, the 70% of the first group had a reduction > 50% of seizure frequency, with six patients becoming also seizure free, while in the second group, only the 23.5% had a reduction > 50% of seizure frequency and none became seizure free (p = 0.005). Six patients of first group were also switched to a monotherapy of PER and five out of six remained seizure free at 12 months. At 1 year of follow-up, efficacy of PER was 70% for the first group, while only of 29.4% for the second group (p = 0.014). Retention rate of the first group at 3 months and 1 year was 85%, while for the second group was, respectively, 82.3% and 64.7%. CONCLUSION: PER was significantly successful and tolerated in MTLE patients when used as first add-on option rather than as late add-on.
Authors: Vicente Villanueva; Javier Montoya; Ascension Castillo; José Á Mauri-Llerda; Pau Giner; Francisco J López-González; Anna Piera; Pedro Villanueva-Hernández; Vicente Bertol; Alejandro Garcia-Escrivá; Juan J Garcia-Peñas; Iñigo Garamendi; Patricia Esteve-Belloch; Juan J Baiges-Octavio; Júlia Miró; Mercè Falip; Mercedes Garcés; Asier Gómez; Francisco J Gil-López; Mar Carreño; Juan J Rodriguez-Uranga; Dulce Campos; Macarena Bonet; Rosa Querol; Albert Molins; Diego Tortosa; Javier Salas-Puig Journal: Epilepsia Date: 2018-07-31 Impact factor: 5.864
Authors: Jacqueline A French; Gregory L Krauss; Victor Biton; David Squillacote; Haichen Yang; Antonio Laurenza; Dinesh Kumar; Michael A Rogawski Journal: Neurology Date: 2012-07-25 Impact factor: 9.910
Authors: Ji Hyun Kim; Dong Wook Kim; Sang Kun Lee; Dae Won Seo; Ji Woong Lee; Hae Joon Park; Sang Ahm Lee Journal: Acta Neurol Scand Date: 2019-12-04 Impact factor: 3.209
Authors: Anna Mammì; Edoardo Ferlazzo; Sara Gasparini; Valentina Bova; Sabrina Neri; Angelo Labate; Giovanni Mastroianni; Concetta Lo Bianco; Vittoria Cianci; Umberto Aguglia Journal: Front Neurol Date: 2022-03-07 Impact factor: 4.003